CRCP
ALXN

Copper Rock Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Copper Rock Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-300
Closed -$47K – 146
2014
Q2 		$47K Hold
300
– – 0.01% 151
2014
Q1 		$46K Hold
300
– – ﹤0.01% 218
2013
Q4 		$40K Hold
300
– – ﹤0.01% 232
2013
Q3 		$35K Buy
+300
New +$32.9K ﹤0.01% 239

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Copper Rock Capital Partners's ALXN Position: Q3 2014 in Review

Copper Rock Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2014, closing a stake of 300 shares — an estimated $47K sold.

Copper Rock Capital Partners first reported a position in ALXN in Q3 2013 and held it in 4 quarters. The position peaked at $47K in Q2 2014. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • Copper Rock Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Copper Rock Capital Partners sold 300 Alexion Pharmaceuticals shares in Q3 2014, an estimated $47K.
  • Copper Rock Capital Partners first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • Copper Rock Capital Partners's Alexion Pharmaceuticals position peaked at $47K in Q2 2014.
  • 522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on Copper Rock Capital Partners's 13F filing for Q3 2014, filed 7 Oct 2014.